41.73

1.24% 0.51

After Hours: 41.73

Springworks Therapeutics Inc (SWTX)

Overview News Price History Option Chain Financials Discussions Forecast

Springworks Therapeutics Inc stock is traded at $41.73, with a volume of 677.58K. It is up +1.24% in the last 24 hours and up +42.37% over the past month. SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Previous Close:

$41.22

Open:

$41.47

24h Volume:

677.58K

Relative Volume:

0.64

Market Cap:

$3.07B

Revenue:

Net Income/Loss:

$-301.06M

P/E Ratio:

-8.5688

EPS:

-4.87

Net Cash Flow:

$-248.01M

1W Performance:

+11.46%

1M Performance:

+42.37%

6M Performance:

-1.53%

1Y Performance:

+100.91%

1-Day Range:

$40.99

$42.38

1-Week Range:

$36.13

$42.38

52-Week Range:

$23.00

$53.92

Springworks Therapeutics Inc Stock (SWTX) Company Profile

Name

Springworks Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

203-883-9490

Address

100 WASHINGTON BOULEVARD, STAMFORD, CT

Employee

305

Twitter

@springworkstx

Next Earnings Date

2024-11-12

Latest SEC Filings

SWTX's Discussions on Twitter

Compare SWTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SWTX Springworks Therapeutics Inc	41.73	3.07B	0	-301.06M	-248.01M	-4.87
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-24	Initiated	Evercore ISI	Outperform
Feb-05-24	Initiated	Guggenheim	Buy
Dec-01-22	Initiated	BofA Securities	Buy
Jan-19-21	Reiterated	H.C. Wainwright	Buy
Oct-29-20	Reiterated	H.C. Wainwright	Buy
May-05-20	Initiated	Barclays	Overweight
Mar-19-20	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-04-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Dec-04-19	Initiated	H.C. Wainwright	Buy
Oct-08-19	Initiated	Cowen	Outperform
Oct-08-19	Initiated	Goldman	Buy
Oct-08-19	Initiated	JP Morgan	Overweight
Oct-08-19	Initiated	Wedbush	Outperform

View All

Springworks Therapeutics Inc Stock (SWTX) Latest News

Nov 26, 2024

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - The Manila Times

Nov 26, 2024

SpringWorks Therapeutics to Present at Evercore ISI HealthCONx Conference | SWTX Stock News - StockTitan

Nov 26, 2024

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewswire Inc.

Nov 26, 2024

Massachusetts Financial Services Co. MA Boosts Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

Nov 26, 2024

(SWTX) Investment Analysis - Stock Traders Daily

Nov 26, 2024

Nov 25, 2024

SpringWorks Therapeutics' SWOT analysis: stock shows promise amid challenges - Investing.com

Nov 25, 2024

Alpha DNA Investment Management LLC Makes New $411,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

Nov 25, 2024

GSA Capital Partners LLP Makes New $209,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World

Nov 25, 2024

Nov 24, 2024

Eagle Asset Management Inc. Sells 54,366 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat

Nov 24, 2024

Nov 23, 2024

SpringWorks Therapeutics (NASDAQ:SWTX) Trading 8.1% HigherShould You Buy? - MarketBeat

Nov 23, 2024

Nov 22, 2024